Estados financieros detallados de ProKidney Corp. (PROK): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto -252.6%, margen operativo -216.6%, margen neto -106.0%.
Al precio actual de $1.85, PROK presenta beneficios negativos (P/E no significativo) y un ROE del 8.83%. La capitalización bursátil es de $622M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | $76000 | $893000 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | $76000 | $893000 |
| I+D | $75.2M | $21.0M | $46.3M | $82.1M | $106.7M | $127.7M | $114.1M |
| Generales y Administrativos | $4.2M | $6.0M | $8.9M | $70.9M | $44.8M | $56.1M | $51.8M |
| Gastos Operativos | $79.4M | $27.0M | $55.1M | $153.0M | $151.5M | $183.8M | $165.9M |
| Beneficio Operativo | -$79.4M | -$27.0M | -$55.1M | -$153.0M | -$151.5M | -$183.7M | -$165.0M |
| EBITDA | -$18.3M | -$26.1M | -$53.1M | -$144.0M | -$125.6M | -$158.5M | -$144.6M |
| Gastos por Intereses | 0 | 0 | 0 | $215000 | $12000 | $9000 | $4000 |
| Beneficio Antes de Impuestos | -$79.3M | -$27.0M | -$55.1M | -$147.2M | -$129.5M | -$163.9M | -$151.2M |
| Impuestos | $361000 | -$232000 | $38000 | $896000 | $6.0M | -$598000 | $414000 |
| Beneficio Neto | -$79.6M | -$26.7M | -$55.1M | -$108.0M | -$35.5M | -$61.2M | -$69.0M |
| BPA | $-1.01 | $-0.14 | $-1.73 | $-1.76 | $-0.57 | $-0.62 | $-0.52 |
| BPA Diluido | $-1.01 | $-0.14 | $-1.73 | $-1.76 | $-0.57 | $-0.62 | $-0.52 |
| Acciones en Circulación (Diluidas) | $78.5M | $186.5M | $31.9M | $61.5M | $61.7M | $97.9M | $133.9M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $217000 | $225000 | $226000 | $150000 |
| Beneficio Bruto | $217000 | -$1.2M | -$1.2M | $150000 |
| Beneficio Operativo | -$38.5M | -$45.4M | -$44.9M | -$48.4M |
| EBITDA | -$33.6M | -$41.0M | -$41.2M | -$45.0M |
| Beneficio Neto | -$16.5M | -$19.2M | -$22.6M | -$28.4M |
| BPA | $-0.12 | $-0.14 | $-0.16 | $-0.15 |
| BPA Diluido | $-0.12 | $-0.14 | $-0.16 | $-0.15 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $15.2M | $4.6M | $20.6M | $490.3M | $60.6M | $99.1M | $108.5M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | $302.3M | $259.2M | $161.5M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | $1.4M | $2.4M | $1.1M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $15.4M | $5.6M | $27.3M | $504.7M | $374.1M | $395.9M | $280.7M |
| Inmovilizado Material | $3.3M | $10.5M | $12.6M | $13.1M | $46.4M | $45.2M | $54.9M |
| Fondo de Comercio | 0 | $641358 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $857000 | $642 | $428000 | $213000 | 0 | 0 | 0 |
| Activos Totales | $19.6M | $16.7M | $40.3M | $518.0M | $420.6M | $441.1M | $335.6M |
| Cuentas por Pagar | $480000 | $781000 | $2.8M | $3.0M | $5.1M | $3.6M | $940000 |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $2.7M | $5.5M | $12.3M | $10.9M | $25.0M | $36.2M | $30.7M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $3.7M | $6.8M | $13.4M | $13.1M | $29.2M | $39.4M | $34.8M |
| Reservas | -$79.6M | -$106.4M | -$161.5M | -$1.10B | -$1.14B | -$1.20B | -$1.27B |
| Patrimonio Neto | $15.9M | $9.9M | $26.9M | -$1.10B | -$1.10B | -$995.0M | -$1.01B |
| Deuda Total | $1.1M | $1.6M | $1.3M | $2.4M | $4.4M | $3.2M | $4.0M |
| Deuda Neta | -$14.1M | -$3.0M | -$19.2M | -$487.9M | -$358.5M | -$355.1M | -$266.0M |
| Capital Circulante | $12.7M | $83000 | $15.0M | $493.8M | $349.1M | $359.7M | $249.9M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $95.3M | $108.5M | $101.9M | $74.9M |
| Activos Totales | $351.6M | $335.6M | $292.8M | $249.0M |
| Pasivos Totales | $33.3M | $34.8M | $29.7M | $26.2M |
| Patrimonio Neto | -$1.01B | -$1.01B | -$1.02B | -$883.5M |
| Deuda Total | $4.2M | $4.0M | $3.8M | $3.5M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$79615 | -$26.7M | -$55.1M | -$148.1M | -$135.4M | -$163.3M | -$151.6M |
| Amortizaciones | $867 | $964000 | $2.0M | $3.0M | $3.9M | $5.4M | $6.6M |
| Compensación en Acciones | $498 | $730000 | $699000 | $74.5M | $30.8M | $29.4M | $25.3M |
| Cambio en Capital Circulante | -$115 | -$126000 | $2.2M | -$6.5M | $16.7M | $4.0M | $1.3M |
| Flujo de Caja Operativo | -$76806 | -$25.2M | -$50.3M | -$77.1M | -$90.1M | -$126.4M | -$120.1M |
| Inversiones (CapEx) | -$1305 | -$5.5M | -$5.2M | -$1.8M | -$34.2M | -$29.5M | -$15.2M |
| Adquisiciones | -$1663 | 0 | $1000 | $108000 | 0 | 0 | $18.2M |
| Recompra de Acciones | 0 | 0 | 0 | 0 | -$9.5M | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$78111 | -$30.6M | -$55.5M | -$78.9M | -$124.3M | -$155.9M | -$135.3M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$26.6M | -$32.5M | -$41.7M | -$40.4M |
| Inversiones (CapEx) | -$5.2M | -$5.8M | -$3.8M | -$3.8M |
| Flujo de Caja Libre | -$31.8M | -$38.3M | -$45.5M | -$44.2M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | $5.7M | $4.9M | $5.6M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | | +1075.0% |
| Crecimiento Beneficio Neto (anual) | | +66.4% | -106.2% | -95.9% | +67.2% | -72.5% | -12.7% |
| Crecimiento BPA (anual) | | +86.1% | -1135.7% | -1.7% | +67.6% | -8.8% | +16.1% |
| Cambio en Acciones (anual) | | +137.5% | -82.9% | +93.0% | +0.3% | +58.7% | +36.8% |
| Crecimiento FCF (anual) | | -39122.4% | -81.1% | -42.2% | -57.4% | -25.4% | +13.2% |
| Margen Bruto | | | | | | 100.0% | 100.0% |
| Margen Operativo | | | | | | -241678.9% | -18477.8% |
| Margen EBITDA | | | | | | -208542.1% | -16194.7% |
| Margen Neto | | | | | | -80507.9% | -7725.2% |
| Margen FCF | | | | | | -205078.9% | -15152.6% |
| Tasa Impositiva Efectiva | -0.5% | 0.9% | -0.1% | -0.6% | -4.6% | 0.4% | -0.3% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.00 | $-0.16 | $-1.74 | $-1.28 | $-2.01 | $-1.59 | $-1.01 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $78.5M | $186.5M | $31.9M | $61.5M | $61.7M | $97.9M | $133.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 8.83% |
| Rentabilidad sobre capital invertido | -68.08% |
| Rentabilidad sobre activos | -34.82% |
| Margen bruto | -252.57% |
| Margen operativo | -21664.55% |
| Margen neto | -10599.76% |
Salud financiera
| Deuda / Patrimonio | -0.00 |
| Ratio corriente | 8.36 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 5.72 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -10.01 | -72.21 | -5.72 | -3.90 | -3.12 | -2.73 | -4.31 |
| P/VC | 49.98 | 191.15 | 11.73 | -0.38 | -0.10 | -0.17 | -0.30 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2177.35 | 335.98 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -241678.9% | -18477.8% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -80507.9% | -7725.2% |